肿瘤标记物联合检测对肺癌诊断的价值

探讨联合检测癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白片段(CYFRA2l—1)在肺癌诊断中的应用价值。应用放射免疫法分别检测75例肺癌患者和22例肺良性疾病患者血清中CEA、NSE、CYFRA21—l水平。结果显示，CEA在肺腺癌中的水平最高，NSE在肺小细胞癌中的水平最高，CYFRA2l—l在肺鳞癌中的水平最高。CEA NSE CYFRA2l—1联合检测肺癌的阳性率为82．67％。提示CEA、NSE、CYFRA2l—l 3项指标联合检测可提高肺癌诊断的阳性率。

THE CLINICAL SIGNIFICANCE OF TUMOR MARKERS COMBINATION MEASUREMENT IN DIAGNOSIS OF LUNG CANCER

To study the clinical significance of combined measurement of neuron specific enolase(NSE), carcinoembryonic antigen(CEA) and Cytokeratin19 fragment 21 1 (CYFRA 21 1 ) in the diagnosis of lung cancer. The serum levels of CEA, NSE, and CYFRA 21 1 in 75 lung cancer patients as well as in 22 benign pulmonary diseases patients were measured by radioimmunoassay. Patients with pulmonary adenocarcinoma had a highest CEA level. Small cell lung carcinoma (SCLC) patients had a highest NSE level, while patients with squamous cell carcinoma of lung had a highest CYFRA 21 1 level. The positive rate of the combination of CEA, NSE, and CYFRA 21 1 for lung cancers was 82 67%. The results suggested that the combined measurement of CEA, NSE, and CYFRA 21 1 was helpful in the diagnosis of lung cancer.